## Extended data Fig1: Age and BMI cohort distributions and Select Medications distribution



## B



## D

Changes in IL-6, according to tocilizumab, after controlling, age, ICU admission and days from symptom onset, accounting for multiple observations per person (GEE).

| Covariate | Coefficient | $95 \% \mathrm{Cl}$ |
| :--- | :--- | :--- |
| Tocilizumab | $\mathbf{0 . 5 5}$ | $\mathbf{0 . 0 7 , 1 . 0 4}$ |
| ICU admission | 0.48 | $-0.02,0.99$ |
| Days from symptom onset | -0.02 | $-0.04,-0.003$ |
| Age | 0.01 | $0.0003,0.02$ |
| This analysis excludes two individuals whose IL-6 was measured before receiving tocilizumab. |  |  |

Changes in T cell count, according to age, ICU admission and days from symptom onset, accounting for multiple observations per person (GEE).

| Covariate | Coefficient | $95 \% \mathrm{Cl}$ |
| :--- | :--- | :--- |
| ICU admission | -13.43 | $-19.32,-7.55$ |
| Days from symptom onset | -0.15 | $-0.41,0.11$ |
| Age | $-\mathbf{0 . 1 6}$ | $\mathbf{- 0 . 3 3 , 0 . 0 2}$ |

## Extended Data Fig. 2: Overview of cellular immune changes in COVID-19 patients



## Extended Data Fig3: Overview of cytokine and chemokine profiles of COVID-19 patients

A


IL9


IL17F


IL27


CCL13


CXCL1


IFNL


IL3


IL10


IL20


IL33


CCL15


CXCL5


IL4


IL22


CCL3


CCL21


TNFb


IL5


CCL2


CCL17


IL7


IL23


CCL4


CCL22


CXCL13


FLT3L




IL25



CCL27


CX3CL1


GCSF


## Extended Data Fig3: Overview of cytokine and chemokine profiles of COVID-19 patients



SCF


TPO


MCSF


EGF


SDF1


Eotaxin


VEGFA


Eotaxin 2



PDGF-AA


LIF
F

Eotaxin 3


PDGF-BB


TRAIL


[^0]

TSLP
 sCD40L


Extendend Data Fig 4: Longitudinal cytokine and chemokine profiles in COVID-19 patients A


IL9



CCL4


CCL21







CCL15



CCL27




CXCL5



CX3CL1








MCSF




Extended Data Fig.5: T cell imune profile in moderate vs. severe patients
A














Extended Fig 6: Early cytokine pofile distinguishes moderate and severe outcomes


CCL8




D


IL1RA








CCL7


CCL13



TNFa


IL6


## Extended Data Fig 7: Distribution of days from symptom onset stratified by collection time point



## Extended Data Fig 8: Risk of death according to biomarkers levels

Risk of death:

A.


















CD3 Brilliant Violet 605-A From CD4 CD45RA
CD25













[^0]:    HCW Moderate Severe

